anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 28,471-28,500
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

28,471-28,500 of 303,780

filter-aware
142
The slide uses direct excerpts from regulatory documents to challenge the company's claims regarding drug safety and pharmacokinetics.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
145
The slide contrasts the author's critique with a direct excerpt from an FDA Clinical Pharmacology Review.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
155
The slide uses a narrative summary followed by a supporting table (Table 4) to challenge the safety reporting of the drug.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
168
The slide uses specific case descriptions to argue for a pattern of respiratory/pulmonary-related deaths.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
170
The slide uses a combination of narrative argument and a cited abstract to highlight a potential safety oversight.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
171
The slide uses two distinct text columns to present evidence from 2008 and 2009 papers regarding the toxicity profile of H3R compounds.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
182
This is a clinical case report document, likely from an FDA FAERS FOIA request.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
183
The slide presents a clinical case study narrative, likely for pharmacovigilance or safety analysis.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
186
The slide presents a clinical case study from the FDA FAERS database, highlighting a potential drug-drug interaction or confounding factor.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
187
This is a clinical case report document from the FDA Adverse Event Reporting System (FAERS).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
188
This is a raw FDA FAERS FOIA case report document.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
190
This slide presents raw clinical case data from the FDA FAERS database to support a hypothesis about drug interactions.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
196
The slide presents a specific pharmacovigilance case report, highlighting a positive dechallenge.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
198
This appears to be a medical case report document from the FDA FAERS database.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
200
This is a pharmacovigilance case report summary.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
202
The slide explicitly frames the narrative as a potential cover-up, contrasting patient statements with official physician office clarifications.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
218
The slide uses visual evidence of four different versions of the ESS form to support the claim that the scale lacks a single, consistent format.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
219
The slide uses a 'villain' framing for the Epworth Sleepiness Scale to justify why it should not be used in the context of the research.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
227
The slide highlights a discrepancy between the reported trial results and the underlying patient-level data regarding dosage and efficacy.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
243
The slide uses red boxes and text annotations to highlight specific data points (M6 for ESS, M12 for cataplexy) that contradict expected outcomes.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
244
The slide uses a comparative analysis of clinical trial data to challenge the validity of the HARMONY 3 results.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
311
The slide uses expert testimony and raw data tables to challenge the validity of the reported pharmacokinetics.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
312
The slide uses a combination of summary text, a screenshot of the original study abstract, and a pull-quote from an expert review to discredit the study's findings.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
314
The slide uses red boxes and text annotations to highlight specific data points in the charts that contradict expected clinical outcomes.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 2 hits
01
Slide 1
The slide serves as a cover page for an activist short report, utilizing strong, accusatory language to frame the company as a fraudulent entity.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Beat · Introduction to Lasertec2 hits
36
The slide provides technical background on EUV masks (blanks vs. reticles) to contextualize the company's niche market position.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Beat · Technical issues with Lasertec's products2 hits
51
The slide uses direct quotes from earnings transcripts to demonstrate a pattern of management opacity.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Beat · Technical issues with Lasertec's productsLoop · The Reveal2 hits
54
The slide uses a 'before-after' comparison of product generations to undermine the company's technological narrative.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Beat · Technical issues with Lasertec's productsLoop · The Reveal2 hits
62
The slide uses a visual 'before and after' logic to show how accounting manipulation impacts the P&L and Balance Sheet equations.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Loop · The Reveal2 hits
63
The slide uses historical financial data to illustrate how accounting manipulation (hiding losses via goodwill/investments) manifests in balance sheet ratios.Lasertec Corporation (6920) · Scorpion Capital
Activist deck Short seller Loop · The Reveal2 hits